<DOC>
	<DOC>NCT02378883</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety of the Apollo™ Onyx™ Delivery Micro Catheter used for delivery of the Onyx™ Liquid Embolic System during brain arteriovenous malformation (AVM) embolization procedures.</brief_summary>
	<brief_title>Apollo™ Onyx™ Delivery Micro Catheter Post Market Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Arteriovenous Malformations</mesh_term>
	<mesh_term>Hemangioma</mesh_term>
	<criteria>The Subject or Subject's legally authorized representative has signed and dated an informed consent form. The Subject has a confirmed diagnosis of a brain AVM. The Subject is clinically and neurologically stable for a minimum of 48 hours prior to embolization. The Subject has a life expectancy of at least 1 year. The Subject agrees to and is capable of completing all studyrequired procedures. Current participation in another investigational drug or device study that evaluates treatments for brain AVMs or other cerebrovascular disease. The Subject has a bleeding disorder. The Subject is not a candidate for the use of vasodilators.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Apollo</keyword>
	<keyword>Onyx</keyword>
	<keyword>arteriovenous malformation</keyword>
	<keyword>AVM</keyword>
	<keyword>Onyx™ Liquid Embolic System</keyword>
	<keyword>Apollo™ Onyx™ Delivery Micro Catheter</keyword>
	<keyword>Brain Diseases</keyword>
</DOC>